|
Published by: Global Industry Analysts
Published: Oct. 1, 2008 - 327 Pages
Table of Contents
- I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions And Scope Of Study
- II. EXECUTIVE SUMMARY
- 1. Worldwide Anticoagulants Market
- Global Market Overview
- Current and Future Scenario
- Major Markets - Products
- Injectable Anticoagulants - On An Up Trend
- Low Molecular Weight Heparins - Ruling the Roost
- Major Markets - Regional
- United States - The Largest Market
- Europe - The Second Largest Market
- 2. Industry Overview
- The Pharmaceuticals Industry
- Industry Framework
- Regulatory Price Controls - Present and Future
- Consolidations Driving the Industry
- Patent Expiries Giving Way to Generic Drugs
- Anticoagulants Sector
- A Snapshot of Available Therapies
- An Insight into Currently Available Antithrombotic Drugs
- Weaknesses of Available Therapies
- Forces Driving the Market
- Oral Anticoagulants Market
- Injectable Anticoagulants Market
- Heparin Market
- LMWH Market
- 3. Market Dynamics
- Drug Advancements Drive Anticoagulant Market
- Niche Markets - The New Target for Drug Makers
- An Opportunity to Grow Further
- Geriatric Patients - At High Risk of Blood Clots
- Improved Anticoagulant Agents for Children Group
- Growing Demand for Self-Testing
- LMWHs Eases Outpatient Management
- Concern Over Underutilization of Warfarin
- Anticoagulants to Lose UA/AMI Markets to Antiplatelets
- Influx of New Drugs: Invigorates the Market
- Novel Heparins: Enhances Market Potential
- Anticoagulant Therapy During Pregnancy Improves Outcomes
- New Therapies: Need of the Hour
- Anticoagulant Therapy in IPF: Reduces Mortality Risk
- Failure of Exanta
- 4. Product Overview
- Introduction to Anticoagulants
- Evolution of Anticoagulants
- Blood Coagulation - A Major Concern
- Anticoagulants Disrupts Metastatic Events
- The Coagulation Cascade
- Coagulation Factors Found in the Coagulation Cascade
- Precautions
- Side Effects
- Hemorrhagic Symptoms and Side Effects
- Impediments
- Potential Candidates for Anticoagulation
- Alternative Therapies to Anticoagulants
- Thrombolytics - Another Major Solution for Thrombosis
- Anticoagulants Drug Class
- Oral Anticoagulants
- Oral Anticoagulants Induces Calcification
- Warfarin
- Advantages and Alternatives
- Side Effects
- Limitations
- Coumadin
- Injectable Anticoagulants
- Heparin - The Backbone of Injectable Anticoagulants
- Unfractionated Heparin
- Advantages and Alternatives
- Limitations
- Low Molecular Weight Heparins
- Costs
- Impediments
- Lovenox/Clexane (enoxaparin)
- Approved Indications for Lovenox:
- Advantages and Alternatives
- Fragmin (dalteparin)
- Approved Indications for Fragmin Use:
- Contradictions
- Precautions
- Fraxiparine (nadroparin)
- Innohep (tinzaparin)
- Contraindications
- Side Effects
- Other Serious Adverse Events Associated with Innohep
- Precautions
- Normiflo (ardeparin)
- Clivarine (reviparin)
- Summary of Available LMWHs
- Non-Heparin Injectables
- Arixtra (fondaparinux)
- Contraindications
- Market and Market Participants
- Angiomax (bivalirudin)
- Advantages
- Contraindications
- Side Effects
- Argatroban/ Novastan
- Side Effects
- Precautions
- Refludan (lepirudin)
- Orgaran (danaparoid sodium)
- Contraindications
- Side Effects
- Caution
- Precaution
- A Comparative Analysis of Various Direct Thrombin Inhibitors
- Other Anticoagulants
- Lithium Heparin
- EDTA
- Citrate
- Oxalate
- 5. A Comparative Study of Anticoagulant Therapies
- A Comparative Study of Warfarin Against LMWHs
- A Comparative Study of LMWH Against UFH
- A Comparative Study of Heparin Against Angiomax
- A Comparative Study of Arixtra Against UFH and LMWH
- A Comparative Study of Angiomax Against UFH and LMWH
- 6. Areas of Indication
- Indications for Anticoagulant Use
- Venous/DVT Thrombosis Indications
- Venous Thromboembolism (VTE)
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Orthopedic (Hip or Knee Replacement) Surgery
- General Surgery
- Cancer
- Arterial Thrombosis Indications
- Arterial Thrombosis
- Acute Coronary Syndromes (ACS)
- Atrial Fibrillation (AF)
- Unstable Angina (UA)
- List of Approved Anticoagulants for Unstable Angina
- Myocardial Infraction (MI)
- Non-ST Segment Elevation MI
- List of Approved Anticoagulants for Non-ST Segment Elevation Myocardial
- Infraction
- Percutaneous Transluminal Coronary Angioplasty (PTCA)
- List of Approved Anticoagulants for Angioplasty Procedures
- Heparin Induced Thrombocytopenia (HIT) Indications
- HIT Type I
- HIT Type II
- Heparin Induced Thrombocytopenia with Thrombosis (HITTS)
- Other Indications
- Hemodialysis
- 7. Drug Development Pipeline
- Select Anticoagulants Under Pipeline
- Idraparinux - Sanofi-Aventis
- 0673 - Sanofi-Aventis
- BIBR1048MS - Boehringer Ingelheim
- 8. Product Introductions
- Boehringer Receives EU Approval for Pradaxa
- Sanofi-Aventis Receives Approval for Clexane® in Japan
- ParagonDx Receives US FDA Approval for its Rapid Genotyping Assay
- Lannett Obtains US FDA Approval for Dipyridamole Tablets
- Kimball Introduces New Pharmacogenetic Test
- Roche Launches an Improved Point-of-Care Anticoagulation Monitoring System
- Danish Agency Grants Approval for Anticoagulant Clinical Trials
- EMEA Approves ARIXTRA® of GlaxoSmithKline
- FDA Approves ANDAs of PLIVA
- FDA Approves ARIXTRA Injection of GSK
- Japanese Ministry Approves Arixtra of GSK
- Eisai Obtains FDA Approval for Fragmin
- Sanofi-Aventis' Lovenox® Obtains FDA Approval for Acute Cardiac Care
- Zydus Cadila's Warfarin Secures Approval from US FDA
- Momenta Pharmaceuticals Seeks Approval for M-Enoxaparin
- Mitsubishi Pharma Releases Argatroban in Europe
- Regado Develops Anticoagulant
- 9. Recent Industry Activity
- PAION Acquires CeNes Pharmaceuticals
- PAION Announces Acquisition of Global Rights to Trigen’s flovagatran
- Biological E Collaborates with Choncept and Heparinex
- Bayer’s Market Expansion
- B. Braun Recalls Heparin Sodium Based Injection Solutions
- Baxter Recalls Heparin Sodium Vials
- Celgene Acquires Pharmion
- BMS Collaborates with Pfizer
- Medicines Company Reacquires European Rights for Angiox
- HemoSense and LabCorp Sign Agreement for Supply of INRatio System
- Sanofi-Aventis Acquires Rights for Panaldine from Daiichi
- Alchemia Inks Marketing Alliance with Dr Reddy’s for Heparin
- Inverness Announces Acquisition of HemoSense
- ev3, FoxHollow Complete Merger
- Osmetech Signs Licensing Agreement with Marshfield Clinic
- Mitsubishi and Tanabe Agree to Merge
- Artisan and A-Bio Form Alliance
- Archemix and Nuvelo Announces Expansion of Alliance
- American Capital Acquires Scientific Protein Laboratories’ One Stop Buyout™
- Bristol-Myers to Start New Facility in Massachusetts
- AstraZeneca Stops Development of Exanta
- Pfizer Enters into Agreement with BPC
- AstraZeneca Pacts with Targacept
- GlaxoSmithKline Acquires ID Biomedical
- Direct Capital Buys Stake in NZP
- Archemix and Nuvelo Stop Development of ARC183
- Novartis Purchases Bristol-Myers’ US/Canadian Consumer Medicine Operations
- Akers Pacts with Cardinal Health
- 10. Focus on Select Global Players
- AstraZeneca PLC (UK)
- Barr Laboratories Inc (USA)
- Bristol-Myers Squibb Company (USA)
- Celgene Corporation (USA)
- GlaxoSmithKline plc (UK)
- Mitsubishi Tanabe Pharma Corporation (Japan)
- Pfizer Inc (USA)
- Sanofi-Aventis (France)
- 11. Global Market Perspective
- Table 1: World Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 2: World Long-term Projections for Anticoagulants by Geographic Region/Country -
- US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales
-
- Figures in US$ Million for Years 2011 through 2015 (includes corresponding
- Graph/Chart)
- Table 3: World 10-Year Perspective for Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- Table 4: World Recent Past, Current & Future Analysis for Oral Anticoagulants by Geographic Region/ Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 5: World Long-term Projections for Oral Anticoagulants by Geographic Region/Country
-
- - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales
- Figures in US$ Million for Years 2011 through 2015 (includes corresponding
- Graph/Chart)
Table 6: World 10-Year Perspective for Oral Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
Table 7: World Recent Past, Current & Future Analysis for Injectable Anticoagulants by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 8: World Long-term Projections for Injectable Anticoagulants by Geographic
Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding
Graph/Chart)
Table 9: World 10-Year Perspective for Injectable Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
Table 10: World Recent Past, Current & Future Analysis for Injectable Anticoagulants by Product Segment - Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 11: World Long-term Projections for Injectable Anticoagulants by Product Segment -
Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart)
Table 12: World 10-Year Perspective for Injectable Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Unfractionated Heparin and Low Molecular Weight Heparin Markets for the Years 2003, 2008 & 2012
Table 13: World Recent Past, Current & Future Analysis for Unfractionated Heparin by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 14: World Long-term Projections for Unfractionated Heparin by Geographic
Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding
Graph/Chart)
Table 15: World 10-Year Perspective for Unfractionated Heparin by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
Table 16: World Recent Past, Current & Future Analysis for Low Molecular Weight Heparin s by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 17: World Long-term Projections for Low Molecular Weight Heparin by Geographic
Region / Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart)
Table 18: World 10-Year Perspective for Low Molecular Weight Heparin by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
III. MARKET
1. The United States
A. Market Overview
- Outlook
- Atrial Fibrillation - A Key Risk Factor
- Regulatory Route to the US Market
Price Controls
- US Anticoagulants Market
- US Heparin Market
Hinging on Market Opportunities
- Generics - Threatening Branded Anticoagulants
List of Patent Protected Anticoagulants in the US
- Ignorance - A Major Hindrance
- Future Challenges and Growth Drivers
- US Emerging Anticoagulant Market
US Emerging Anticoagulants Market: Products in the Pipeline
- Product Introductions
Strategic Corporate Developments
Focus on Select Players
B. Market Analytics
- Table 19: US Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 20: US Long-term Projections for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 21: US 10-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
2. Japan
A. Market Overview
- Pharmaceutical Industry in Japan
- Regulatory Procedure in Japan
- Drug Pricing in Japan
Anticoagulants Market in Japan
- Rising Incidence of Pulmonary Thromboembolism
- Product Introductions
Strategic Corporate Developments
- Mitsubishi Tanabe Pharma Corporation - A Major Player
B. Market Analytics
- Table 22: Japanese Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 23: Japanese Long-term Projections for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 24: Japanese 10-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
3. Europe
A. Market Overview
- An Analysis of Major Regional Markets
- France - A Major Market
- UK - High Growth Potential Market
- Pharmaceutical Industry in Europe
- Regulatory Procedure in Europe
Anticoagulants Market in Europe
- List of Patent Protected Anticoagulants in Europe
- Injectable Sector - Booming Ahead
- Market in High Need of an Ideal Therapy
Product Introductions
- Strategic Corporate Development
B. Market Analytics
- Table 25: European Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 26: European Long-term Projections for Anticoagulants by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 27: European 10-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
Table 28: European Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 29: European Long-term Projections for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 30: European 10-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
3a. France
A. Market Overview
- Sanofi-Aventis - A Major Player
B. Market Analytics
- Table 31: French Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 32: French Long-term Projections for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 33: French 10-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
3b. Germany
A. Market Overview
- Market Drivers for Injectable Anticoagulants
- Anticoagulants Growth Drive European POC Testing Market
- Strategic Corporate Developments
B. Market Analytics
- Table 34: German Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 35: German Long-term Projections for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 36: German 10-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
3c. Italy
Market Analysis
- Table 37: Italian Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 38: Italian Long-term Projections for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 39: Italian 10-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
3d. The United Kingdom
A. Market Overview
- Outlook
- Growing AF Market for Warfarin
- Select Players
Strategic Corporate Developments
B. Market Analytics
- Table 40: UK Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 41: UK Long-term Projections for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 42: UK 10-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
3e. Spain
Market Analysis
- Table 43: Spanish Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 44: Spanish Long-term Projections for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 45: Spanish 10-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
3f. Rest of Europe
Market Analysis
- Table 46: Rest of Europe Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 47: Rest of Europe Long-term Projections for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 48: Rest of Europe 10-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
4. Rest of World
A. Market Overview
- Anticoagulants Market in Australia
- Strategic Corporate Developments
B. Market Analytics
- Table 49: Rest of World Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
Table 50: Rest of World Long-term Projections for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 51: Rest of World 10-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE 179 $995
Total Companies Profiled: 51 (including Divisions/Subsidiaries - 55)
Region/Country Players
The United States28
Canada1
Japan 2
Europe 13
France 1
Germany4
The United Kingdom 4
Rest of Europe 4
Asia-Pacific (Excluding Japan)9
Middle East 2
AbstractThis report analyzes the worldwide markets for Anticoagulants in Millions of US$. The major product segments analyzed are Oral Anticoagulants, and Injectable Anticoagulants (Unfractionated Heparin, and Low Molecular Weight Heparin). The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 51 companies including many key and niche players worldwide such as AstraZeneca PLC, Barr Laboratories Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline plc, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc, and Sanofi-Aventis. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Titles available via "online download" are not affected by this and are still delivered to your reading room immediately.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
